標(biāo)題: Titlebook: Disease-modifying Therapy in Vasculitides; Cees G. M. Kallenberg,Jan W. Cohen Tervaert Book 2001 Birkh?user Verlag 2001 Internal medicine. [打印本頁(yè)] 作者: hexagon 時(shí)間: 2025-3-21 19:54
書目名稱Disease-modifying Therapy in Vasculitides影響因子(影響力)
書目名稱Disease-modifying Therapy in Vasculitides影響因子(影響力)學(xué)科排名
書目名稱Disease-modifying Therapy in Vasculitides網(wǎng)絡(luò)公開度
書目名稱Disease-modifying Therapy in Vasculitides網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Disease-modifying Therapy in Vasculitides被引頻次
書目名稱Disease-modifying Therapy in Vasculitides被引頻次學(xué)科排名
書目名稱Disease-modifying Therapy in Vasculitides年度引用
書目名稱Disease-modifying Therapy in Vasculitides年度引用學(xué)科排名
書目名稱Disease-modifying Therapy in Vasculitides讀者反饋
書目名稱Disease-modifying Therapy in Vasculitides讀者反饋學(xué)科排名
作者: 可轉(zhuǎn)變 時(shí)間: 2025-3-22 00:10
1422-7746 dicine, connective tissue disease and clinical immunology, they present new concepts in classificiation, diagnosis and pathophysiology of the vasculitides. Evidence from experimental and clinical trials is reviewed, as well as the outlook for further research.978-3-0348-9485-2978-3-0348-8235-4Series ISSN 1422-7746 Series E-ISSN 2296-4525 作者: uveitis 時(shí)間: 2025-3-22 02:50
Philip Michalk,Bertram Meimbresse rheumatoid arthritis (RA) and Crohn’s disease has revolutionized the treatment of these diseases [.-.]. The extrapolation and rigorous testing of cytokine modulation strategies in the vasculitides have enormous potential to improve therapies for this group of disorders.作者: SEED 時(shí)間: 2025-3-22 05:08 作者: 色情 時(shí)間: 2025-3-22 10:26 作者: NOCT 時(shí)間: 2025-3-22 16:28
Intravenous immunoglobulin as immuno-modifying treatment,s of autoimmunity. There has been widespread clinical use of IgIV as a second line treatment for many autoimmune diseases with relatively few randomised studies demonstrating its clinical effectiveness.作者: NOCT 時(shí)間: 2025-3-22 17:33 作者: conflate 時(shí)間: 2025-3-22 23:06 作者: 天空 時(shí)間: 2025-3-23 05:23 作者: 似少年 時(shí)間: 2025-3-23 09:37
,Interferon-α for the treatment of virus-related systemic vasculitides,itides with IFNα. Two types of IFNα are commonly prescribed, IFNα 2a and IFNα 2b. They differ by one amino acid but no difference in efficacy has been shown. The other types of IFN, that is, IFNβ and IFNγ, are not prescribed for virus-associated vasculitides.作者: Alopecia-Areata 時(shí)間: 2025-3-23 13:23
Book 2001e of knowledge and concentrates on principles of immune modulating therapy. Drawing from their work in rheumatology, nephrology, internal medicine, connective tissue disease and clinical immunology, they present new concepts in classificiation, diagnosis and pathophysiology of the vasculitides. Evid作者: Ceremony 時(shí)間: 2025-3-23 16:42
1422-7746 rrent state of knowledge and concentrates on principles of immune modulating therapy. Drawing from their work in rheumatology, nephrology, internal medicine, connective tissue disease and clinical immunology, they present new concepts in classificiation, diagnosis and pathophysiology of the vasculit作者: 進(jìn)步 時(shí)間: 2025-3-23 18:19
Progress in Inflammation Researchhttp://image.papertrans.cn/e/image/281270.jpg作者: Fortify 時(shí)間: 2025-3-24 01:31
https://doi.org/10.1007/978-3-0348-8235-4Internal medicine; bacteria; clinical trial; immunoglobulin; immunology; interferon; necrosis; pathophysiol作者: 改正 時(shí)間: 2025-3-24 03:20 作者: Foreshadow 時(shí)間: 2025-3-24 07:20
Disease-modifying Therapy in Vasculitides978-3-0348-8235-4Series ISSN 1422-7746 Series E-ISSN 2296-4525 作者: habitat 時(shí)間: 2025-3-24 12:15 作者: 能得到 時(shí)間: 2025-3-24 18:32 作者: 淘氣 時(shí)間: 2025-3-24 21:28
Philip Michalk,Bertram Meimbressedecade, molecular biology provided not only the techniques to investigate individual cytokines in inflammation, but also successful strategies for the inhibition of these cytokines. As described below, the identification of tumor necrosis factor (TNF) as a critical cytokine in the pathophysiology of作者: Discrete 時(shí)間: 2025-3-25 00:10
https://doi.org/10.1007/978-3-642-23550-4nge of immunoregulatory properties and has, since the early 1980s, excited interest as a therapy for autoimmune disease. Attention has focused on the mechanisms of the therapeutic effects of IgIV and the contribution an understanding of these mechanisms has made to knowledge of the immunopathogenesi作者: REP 時(shí)間: 2025-3-25 04:54
Sustainable Transport Models by Simulation take a lethal course or result in severe permanent organ damage. Although the majority of cases does respond to daily oral cyclophosphamide and corticosteroids [.], the standard induction therapy fails to induce remission in about 5% to 10% of patients. Furthermore, relapses occur in 10% to 20% of 作者: 赤字 時(shí)間: 2025-3-25 09:10 作者: 彩色的蠟筆 時(shí)間: 2025-3-25 15:08
New York’s GreenLITES Rating Systemsfferent purposes: (1) a specific antiviral treatment in virus-related vasculitides; (2) an immunomodulating therapy specifically or non-specifically targeting the vasculitic process and not its etiology; (3) a treatment that reduces liver fibrosis progression [.]. Only IFNα has been prescribed for v作者: Anguish 時(shí)間: 2025-3-25 16:01
K. Thirumaran,G. Balaji,N. Devi Prasadeases a disturbed immune response results in an attack by the immune system on host antigens with B- and T-cell components involved in the process. The hypothesis behind SCT in autoimmune disease is that a vigorous immuno-ablative preparation regimen (“conditioning”) can delete the patient’s immune 作者: Obedient 時(shí)間: 2025-3-25 21:13 作者: 膽大 時(shí)間: 2025-3-26 01:33
Systemic vasculitides, an introduction,e involved vessels as well as on the nature of the inflammatory process. Vasculitis can be secondary to other conditions or constitute a primary, in most cases, idiopathic disorder. Underlying conditions in the secondary vasculitides are infectious diseases, connective tissue diseases, and hypersens作者: companion 時(shí)間: 2025-3-26 07:04 作者: GUISE 時(shí)間: 2025-3-26 10:12 作者: FLORA 時(shí)間: 2025-3-26 15:53
Intravenous immunoglobulin as immuno-modifying treatment,nge of immunoregulatory properties and has, since the early 1980s, excited interest as a therapy for autoimmune disease. Attention has focused on the mechanisms of the therapeutic effects of IgIV and the contribution an understanding of these mechanisms has made to knowledge of the immunopathogenesi作者: Cupidity 時(shí)間: 2025-3-26 20:13 作者: 貪心 時(shí)間: 2025-3-26 23:25
New immunosuppressants: mycophenolate mofetil and 15-deoxyspergualin,vessels leading to vessel wall necrosis and (partial) obliteration or thrombosis of the vascular lumen. Clinical signs and symptoms are caused by disruption of adequate macro-and microcirculatory blood flow of organs or tissues by the vascular inflammatory proces. The classification of these idiopat作者: beta-carotene 時(shí)間: 2025-3-27 01:24
,Interferon-α for the treatment of virus-related systemic vasculitides,fferent purposes: (1) a specific antiviral treatment in virus-related vasculitides; (2) an immunomodulating therapy specifically or non-specifically targeting the vasculitic process and not its etiology; (3) a treatment that reduces liver fibrosis progression [.]. Only IFNα has been prescribed for v作者: Esophagitis 時(shí)間: 2025-3-27 08:44 作者: 裝入膠囊 時(shí)間: 2025-3-27 11:16 作者: 沖擊力 時(shí)間: 2025-3-27 16:47 作者: bifurcate 時(shí)間: 2025-3-27 20:22
Financing Higher Education in Nigeriaimprove therapeutic protocols for vasculitis since current protocols are toxic, contribute to morbidity and mortality, and are not always effective. Novel approaches that recently became available include therapy with mycophenolate and/or 15-deoxyspergualin (see the chapter by Stegeman and Birck in 作者: objection 時(shí)間: 2025-3-28 00:39 作者: GNAT 時(shí)間: 2025-3-28 05:53
https://doi.org/10.1007/978-3-662-46924-8ied. The possible autoimmune origin of these diseases is supported by the strong association of the presence of autoantibodies directed against neutrophil cytoplasmic antigens, so-called anti-neutrophil cytoplasmic antibodies (ANCA), in some of the primary small vessel vasculitides [., .].作者: Middle-Ear 時(shí)間: 2025-3-28 10:06
K. Thirumaran,G. Balaji,N. Devi Prasadronment. Alternatively, the newly developed immune system may develop tolerance to the antigenic trigger allowing an effective cure of the autoimmune disease. However, more simply, a third explanation is that prolonged remission is induced through immune response modulation secondary to the intensiv作者: 演繹 時(shí)間: 2025-3-28 13:05 作者: TRACE 時(shí)間: 2025-3-28 16:53 作者: 無(wú)力更進(jìn) 時(shí)間: 2025-3-28 20:46
T-cell directed treatment: anti-thymocyte globulin, with a cumulative dose higher than 100 g [.]. There is a definite need to replace cyclophosphamide in these refractory cases. In other patients, standard treatment has to be avoided because severe side-effects already developed. Few patients have been reported to have responded to Cyclosporin A [.]作者: mortgage 時(shí)間: 2025-3-29 02:19 作者: cleaver 時(shí)間: 2025-3-29 06:22 作者: Antioxidant 時(shí)間: 2025-3-29 09:39
Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-verapy after a remission is induced with cyclophosphamide and steroids [.]. Azathioprine is considered less effective in inducing remission than cyclophosphamide, but its long-term toxicity is much lower [., .]. The potential of azathioprine as maintenance therapy was recently investigated and compar作者: Cerebrovascular 時(shí)間: 2025-3-29 12:29
10樓作者: Nibble 時(shí)間: 2025-3-29 18:14
10樓作者: 共棲 時(shí)間: 2025-3-29 20:00
10樓
